Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: A phase II study

Abstract

A total of 50 patients with advanced pancreatic cancer were enrolled in a phase II study of bevacizumab 15mgkg1, capecitabine 1300mgm 2 daily for 2 weeks and gemcitabine 1000mgm2 weekly 2 times; cycles were repeated every 21 days. Radiological response rate was 22; progression-free survival and over survival were 5.8 and 9.8 months respectively. Grade 3 or 4 toxicities included neutropaenia (22), thrombocytopaenia (14), thromboembolic events (12), hypertension (8) and haemorrhage (6). © 2009 Cancer Research UK.